Xeris Biopharma Holdings Inc Dossier
Qualitative Analysis
Business overview
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with chronic endocrine and neurological diseases. The company's commercial portfolio is anchored by three key products: Recorlev (levoketoconazole) for endogenous Cushing's syndrome, Gvoke (ready-to-use liquid glucagon) for severe hypoglycemia, and Keveyis (dichlorphenamide) for primary periodic paralysis. Xeris leverages its proprietary formulation technology platforms, XeriSol and XeriJect, to optimize the delivery of existing drugs and biologics. Its lead pipeline candidate is XP-8121, a Phase 3-ready, once-weekly subcutaneous levothyroxine injection designed to bypass the gastrointestinal tract and address therapeutic complications in hypothyroidism.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Nearly doubling the Recorlev sales force to approximately 80 representatives and expanding the target physician base from 7,000-8,000 to approximately 12,000.
Expected impact: Accelerate market penetration and patient demand for Recorlev in the endogenous Cushing's syndrome market.
Advancing XP-8121, a once-weekly subcutaneous injection of levothyroxine designed to bypass gastrointestinal absorption issues in hypothyroid patients, into Phase 3 clinical trials.
Expected impact: Targets a $1 billion to $3 billion peak annual net sales opportunity by 2035.
Leveraging the proprietary XeriSol and XeriJect formulation platforms to establish strategic collaborations and out-licensing agreements with global biopharmaceutical companies.
Expected impact: Provides upfront payments, milestone achievements, and potential royalties, offering a capital-efficient mechanism to diversify revenue streams.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Validates the XeriJect platform's capability to deliver ultra-highly concentrated, ready-to-use, small-volume subcutaneous injections of monoclonal antibodies (mAbs).
Terms: Under the terms of the agreement, Xeris utilizes XeriJect to formulate two undisclosed Regeneron mAbs, with potential for future licensing options.
Evaluates the XeriJect suspension-based formulation technology for use with Merck's undisclosed monoclonal antibodies to engineer ready-to-use subcutaneous formulations.
Terms: Xeris granted Merck an option to license the technology for the formulated molecules under negotiated terms.